Search
for
Sort by
Research 151–180 of 309
- Selective blockade of γc pathway ameliorates alopecia areata in a humanized murine model
- Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan
- Generic vs. Disease-Specific Patient Reported Outcome (PRO) Instruments for Assessing HRQoL Burden Among Patients Diagnosed with Alopecia Areata: Evidence from TARGET-DERM AA
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- Sustained hair regrowth with ritlecitinib to Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
- Impact of Disease History on the Efficacy of Ritlecitinib in Patients With Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- 42005 Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
- Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- 598 Response to ritlecitinib treatment based on salt improvement scores in patients with alopecia areata (AA): Post hoc analysis of the allegro phase 2b/3 study
- Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
- Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results from ALLEGRO-2b/3
- Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies
- Probing the Effects of Stress Mediators on the Human Hair Follicle
- The stumptailed macaque as a model for androgenetic alopecia: Effects of topical minoxidil analyzed by use of the folliculogram
- KF19418, a new compound for hair growth promotion in vitro and in vivo mouse models
- The effects of topical diazoxide on hair follicular growth and physiology of the stumptailed macaque
- Geranyl Acetate Attenuates Para-phenylenediamine-induced Cytotoxicity, DNA Damage, Apoptosis, and Inflammation in HaCaT Keratinocytes
- SRD5A3 Is Required for Converting Polyprenol to Dolichol and Is Mutated in a Congenital Glycosylation Disorder
- pH-Responsive Nanogels from Bioinspired Comb-like Polymers with Hydrophobic Grafts for Effective Oral Delivery
- Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program
- Updated Integrated Safety Analysis of Ritlecitinib Up to ~5 Years in Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- 723 - Efficacy of ritlecitinib in patients with alopecia areata by extent of hair loss at baseline: post hoc analysis of the phase 3 long-term ALLEGRO-LT study
- 75893 Long-term efficacy, complete scalp hair regrowth and normal body hair/nails in adolescents with severe alopecia areata (AA) receiving ritlecitinib up to 3 years in the ALLEGRO clinical trials
- Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
- Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program
- Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
- 75810 Long-term efficacy, complete scalp hair regrowth, and normal body hair and nails in patients with alopecia areata (AA) receiving ritlecitinib 50 mg once daily up to 3 years in the ALLEGRO clinical trial program
- Correction to ‘Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study’
- 125: Individual Severity of Alopecia Tool (SALT) score trajectories of roll-over adolescent patients with alopecia areata (AA) treated with ritlecitinib in the ongoing long-term, open-label, phase 3 ALLEGRO-LT study